Drugs / FDQ22A-NH
last change Mar 2024 re-read 3 minutes ago

FDQ22A-NH

Developed for
influenza
Investigated by
CureVac · GlaxoSmithKline

Trials 1

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05446740 Aug 2022 → Mar 2024 influenza GlaxoSmithKline Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as FDQ22A-NH ClinicalTrials.gov intervention name — accepted as the source's own label NCT05446740 ↗